A new class of drugs is set to join their ranks and has the potential to eclipse them all—GLP-1 receptor agonists ... drugs as preventive treatments. Chart: The Economist GLP-1 drugs are ...
then the goal would be to combine them with GLP-1 agonist GSBR-1290 to treat patients with obesity. The third risk to consider would be in terms of competition in the obesity space. For instance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback